Cambridge Healthtech Institute’s 5th Annual

Neoantigen Targeted Therapies and Personalized Cancer Vaccines

Personalized Cancer Immunotherapy in the Genomic Era

August 13-14, 2020

Fueled with advances in genomic technologies, personalized oncology promises to innovate cancer therapy and target previously undruggable space. Developments in NGS technology enabled systematic analysis of patient-specific mutanome and opened the door to developing personalized cancer vaccines and other therapies targeting neoantigens. Cambridge Healthtech Institute’s Fifth Annual Neoantigen Targeted Therapies and Personalized Cancer Vaccines meeting brings together thought leaders from pharmaceutical and biotech companies, leading academic teams and clinical immuno-oncologists to share research and case studies in implementing patient-centric approaches to using the immune system to beat cancer, including utilizing NGS to identify tumor-specific neoantigens, using in silico tools to predict immunogenic neoepitopes, and targeting them with personalized vaccines, novel antibodies or combination therapies.

Preliminary Agenda


Clinical Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes

Philip Arlen, MD, President & CEO, Precision Biologics

Talk Title to be Announced

Stephen Schoenberger, PhD, Co-Director, San Diego Center for Precision Immunotherapy; Professor, La Jolla Institute for Allergy and Immunology

Talk Title to be Announced

Karin Jooss, PhD, CSO, Gritstone Oncology

True Tumor-Rejection Mediating Neo-Epitopes – Embarrassment of Riches

Pramod Srivastava, MD, PhD, Director, Carole and Ray Neag Comprehensive Cancer Center; Professor, Immunology and Medicine, University of Connecticut School of Medicine


Updated Approaches for Neoantigen Vaccination for Oncology

David A. Reardon, MD, Professor, Medicine, Harvard Medical School; Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute

Bringing Personalized Cancer Vaccines to the Patients: Update on Clinical Data, Challenges and Learnings from the VB N-01 Clinical Study

Agnete Fredriksen, PhD, CSO, Vaccibody

Personalized Treatments for Cancer – At the Intersection of Precision Medicine and Immunotherapy

Niranjan Y. Sardesai, PhD, Co-Founder, President & CEO, Geneos Therapeutics

Th17-Inducing Vaccines for the Treatment of Cancer

Keith Knutson, PhD, Professor, Immunology; Director, Immunology & Immunotherapy Program, Mayo Clinic

Can Vaccination Overcome Immune Ignorance and Segregation within the Tumor Microenvironment?

Robert Pierce, MD, Scientific Director, Immunopathology Core, Fred Hutchinson Cancer Research Center


Oncolytic Immunotherapy Combinations in Pancreatic Cancer

Christos Fountzilas, MD, Assistant Professor, Oncology, Roswell Park Comprehensive Cancer Center

Use of Enveloped Virus-Like Particles (eVLPs) in Immuno-Oncology

David Anderson, PhD, CSO, Research & Development, VBI Vaccines, Inc.

Effective Vaccination with Adenoviral Vectors Encoding Multiple Neoantigens Drives Clonal Expansion of T Cells Infiltrating the Tumors

Elisa Scarselli, MD, CSO, Nouscom AG

* The program is subject to change without notice, due to unforeseen reason.

Choose your language